Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sima P Porten

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
European Urology|May 22, 2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder CancerMarie-Pier St-Laurent, Parminder Singh, David J McConkey, et al.
European Urology Oncology|March 25, 2020
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific DifferencesJoep J de Jong, Joost L Boormans, Bas W G van Rhijn, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2016
Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical CystectomyBrian C Baumann, Walter R Bosch, Amit Bahl, et al.
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
JCO Precision Oncology|June 12, 2024
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy CandidatesUttam Satyal, Henkel Valentine, David Liu, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
European Urology|May 22, 2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder CancerMarie-Pier St-Laurent, Parminder Singh, David J McConkey, et al.
European Urology Oncology|March 25, 2020
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific DifferencesJoep J de Jong, Joost L Boormans, Bas W G van Rhijn, et al.
International Journal of Radiation Oncology, Biology, Physics|August 12, 2016
Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical CystectomyBrian C Baumann, Walter R Bosch, Amit Bahl, et al.
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
JCO Precision Oncology|June 12, 2024
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy CandidatesUttam Satyal, Henkel Valentine, David Liu, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.
Pageof 9